StockData
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc. (VYGR) stock

VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.52−0.11 (-6.75%)

Close on Nov 17, 2026Market cap $93.66MP/E –Yield –

Voyager Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Voyager Therapeutics's pe ratio was 9.4× on Jan 31, 2025, against 2.9× a year earlier. Over the last 4 years it ranged from 0.3× to 45.5×, with a median of 5.0×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jan 31, 20259.4×−0.4
2024Dec 31, 20249.8×+2.9
2023Dec 29, 20236.9×−1.0
2021Oct 29, 20217.9×+1.0
2020Dec 31, 20206.9×−6.0
2017Jul 31, 201712.9×+5.3
2016Dec 30, 20167.6×+6.9
2015Dec 31, 20150.7×–

More Voyager Therapeutics figures

See a number that looks wrong?